While working to catch up with other vaccine developers in the race for a respiratory syncytial virus (RSV) vaccine, San Francisco-based Vaxart this week unveiled data demonstrating its candidate's ability to create a "substantial" immune response in a preclinical challenge model.
Swiss med tech player Debiotech has partnered to develop a next-gen artificial pancreas for diabetics with a pair of Swiss research centers. The aim is to improve upon the accuracy of automatic insulin delivery by using a microelectromechanical system to control the pump. It will be based on an algorithm designed to estimate patient needs based on their measured glucose levels, the time of day and anticipated activities to adjust the infusion rate from an insulin pump.
Aduro BioTech, developing an immunotherapy combination treatment for cancer, watched its share price dip on Tuesday after quietly disclosing that a trial patient developed a serious infection tied to the company's re-engineered bacterial treatment.
Cambridge, MA's Bind Therapeutics announced that patient administration of its Accurins nanoparticles has commenced in the trial of an AstraZeneca cancer candidate. Under the terms of the 2013 partnership with the Big Pharma, Bind earns a milestone payment of $4 million.
Apnea, or a prolonged pause in breathing, is quite common among premature and low-birth-weight infants and can be life-threatening. A trial at the Beth Israel Deaconess Medical Center in 36 infants with apnea of a new mattress vibration device cut the number of apnea events in half. It also improved the infant's oxygenation levels and incidents of a too-slow heart rate.
Animal health companies have been rolling out wearable devices that allow owners to monitor their dog's well-being. Now researchers are developing a device that lets people who are blind keep tabs on their guide dog's health.
Payers have complained loudly about the cost of next-gen hep C meds from Gilead and AbbVie, arguing that the drugs should be reserved for the sickest patients. But now insurers are facing some evidence to the contrary, as a new study shows that new hep C meds are cost-effective when taken in early stages of the disease.
Pills and patches are two drug delivery methods many patients would prefer to needles, especially when it comes to the number of injections a diabetic needs throughout the day. And now, researchers at UC Santa Barbara have combined the two to deliver insulin effectively across the intestinal wall into the blood, which could help overcome the difficulties in developing oral insulin.
ProQR Therapeutics has pushed back the date on which it expects to deliver data from its cystic fibrosis clinical trials. The delay means it may be late 2016 before ProQR presents data on its challenger to Vertex Pharmaceuticals' grip on the cystic fibrosis market.
Genmab's plans to develop ofatumumab for lymphoma came to a halt as the company pulled the plug early on a Phase III trial that was unlikely to meet its goals, souring an investment from partner Novartis.